vs
Side-by-side financial comparison of Bristol Myers Squibb (BMY) and Viatris (VTRS), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
Bristol Myers Squibb is the larger business by last-quarter revenue ($12.5B vs $3.7B, roughly 3.4× Viatris). On growth, Viatris posted the faster year-over-year revenue change (5.0% vs 1.3%). Bristol Myers Squibb produced more free cash flow last quarter ($1.6B vs $619.3M). Over the past eight quarters, Bristol Myers Squibb's revenue compounded faster (2.6% CAGR vs 0.5%).
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid art...
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
BMY vs VTRS — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $12.5B | $3.7B |
| Net Profit | $1.1B | — |
| Gross Margin | 67.2% | 31.1% |
| Operating Margin | 11.8% | -5.2% |
| Net Margin | 8.7% | — |
| Revenue YoY | 1.3% | 5.0% |
| Net Profit YoY | 1409.7% | — |
| EPS (diluted) | $0.54 | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align — see 8-quarter trend below.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | $12.5B | $3.7B | ||
| Q3 25 | $12.2B | $3.7B | ||
| Q2 25 | $12.3B | $3.6B | ||
| Q1 25 | $11.2B | $3.2B | ||
| Q4 24 | $12.3B | $3.5B | ||
| Q3 24 | $11.9B | $3.7B | ||
| Q2 24 | $12.2B | $3.8B | ||
| Q1 24 | $11.9B | $3.7B |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $72.0M | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | $-11.9B | — |
| Q4 25 | 67.2% | 31.1% | ||
| Q3 25 | 71.9% | 36.6% | ||
| Q2 25 | 72.5% | 37.3% | ||
| Q1 25 | 72.9% | 35.8% | ||
| Q4 24 | 61.0% | 34.6% | ||
| Q3 24 | 75.1% | 39.0% | ||
| Q2 24 | 73.2% | 38.2% | ||
| Q1 24 | 75.3% | 41.2% |
| Q4 25 | 11.8% | -5.2% | ||
| Q3 25 | 25.5% | 4.8% | ||
| Q2 25 | 14.5% | 6.5% | ||
| Q1 25 | 26.5% | -88.9% | ||
| Q4 24 | 1.4% | -5.1% | ||
| Q3 24 | 14.1% | 6.0% | ||
| Q2 24 | 10.5% | -6.3% | ||
| Q1 24 | -97.1% | 5.6% |
| Q4 25 | 8.7% | — | ||
| Q3 25 | 18.0% | — | ||
| Q2 25 | 10.7% | — | ||
| Q1 25 | 21.9% | — | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 10.2% | — | ||
| Q2 24 | 13.8% | — | ||
| Q1 24 | -100.4% | — |
| Q4 25 | $0.54 | $-0.34 | ||
| Q3 25 | $1.08 | $-0.11 | ||
| Q2 25 | $0.64 | $0.00 | ||
| Q1 25 | $1.20 | $-2.55 | ||
| Q4 24 | $0.05 | $-0.43 | ||
| Q3 24 | $0.60 | $0.08 | ||
| Q2 24 | $0.83 | $-0.27 | ||
| Q1 24 | $-5.89 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest filing — the kind of financial-strength check premium terminals charge for.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.2B | $1.3B |
| Total DebtLower is stronger | $44.8B | — |
| Stockholders' EquityBook value | $18.5B | $14.7B |
| Total Assets | $90.0B | $37.2B |
| Debt / EquityLower = less leverage | 2.43× | — |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $10.2B | $1.3B | ||
| Q3 25 | $15.7B | $975.3M | ||
| Q2 25 | $12.6B | $566.4M | ||
| Q1 25 | $10.9B | $755.0M | ||
| Q4 24 | $10.3B | $734.8M | ||
| Q3 24 | $7.9B | $1.9B | ||
| Q2 24 | $6.3B | $917.2M | ||
| Q1 24 | $9.3B | $1.0B |
| Q4 25 | $44.8B | — | ||
| Q3 25 | $48.7B | — | ||
| Q2 25 | $48.9B | — | ||
| Q1 25 | $49.5B | — | ||
| Q4 24 | $49.4B | — | ||
| Q3 24 | $49.5B | — | ||
| Q2 24 | $52.0B | — | ||
| Q1 24 | $52.4B | — |
| Q4 25 | $18.5B | $14.7B | ||
| Q3 25 | $18.6B | $15.2B | ||
| Q2 25 | $17.4B | $15.6B | ||
| Q1 25 | $17.4B | $15.7B | ||
| Q4 24 | $16.3B | $18.6B | ||
| Q3 24 | $17.1B | $19.8B | ||
| Q2 24 | $17.0B | $19.5B | ||
| Q1 24 | $16.5B | $20.0B |
| Q4 25 | $90.0B | $37.2B | ||
| Q3 25 | $96.9B | $37.9B | ||
| Q2 25 | $94.7B | $38.4B | ||
| Q1 25 | $92.4B | $38.5B | ||
| Q4 24 | $92.6B | $41.5B | ||
| Q3 24 | $93.7B | $44.8B | ||
| Q2 24 | $94.6B | $45.3B | ||
| Q1 24 | $99.0B | $47.3B |
| Q4 25 | 2.43× | — | ||
| Q3 25 | 2.63× | — | ||
| Q2 25 | 2.81× | — | ||
| Q1 25 | 2.85× | — | ||
| Q4 24 | 3.03× | — | ||
| Q3 24 | 2.89× | — | ||
| Q2 24 | 3.05× | — | ||
| Q1 24 | 3.18× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Net income can be massaged; cash flow is harder to fake.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0B | $815.8M |
| Free Cash FlowOCF − Capex | $1.6B | $619.3M |
| FCF MarginFCF / Revenue | 12.8% | 16.8% |
| Capex IntensityCapex / Revenue; lower = less reinvestment burden | 3.0% | 5.3% |
| Cash ConversionOCF / Net Profit; >1× = earnings back up with cash | 1.82× | — |
| TTM Free Cash FlowTrailing 4 quarters | $12.8B | $1.9B |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $2.0B | $815.8M | ||
| Q3 25 | $6.3B | $744.9M | ||
| Q2 25 | $3.9B | $219.7M | ||
| Q1 25 | $2.0B | $535.5M | ||
| Q4 24 | $4.4B | $482.7M | ||
| Q3 24 | $5.6B | $826.5M | ||
| Q2 24 | $2.3B | $379.1M | ||
| Q1 24 | $2.8B | $614.6M |
| Q4 25 | $1.6B | $619.3M | ||
| Q3 25 | $6.0B | $658.1M | ||
| Q2 25 | $3.6B | $166.8M | ||
| Q1 25 | $1.7B | $492.9M | ||
| Q4 24 | $4.1B | $342.3M | ||
| Q3 24 | $5.3B | $749.5M | ||
| Q2 24 | $2.1B | $320.3M | ||
| Q1 24 | $2.5B | $564.8M |
| Q4 25 | 12.8% | 16.8% | ||
| Q3 25 | 49.0% | 17.6% | ||
| Q2 25 | 29.0% | 4.7% | ||
| Q1 25 | 15.1% | 15.2% | ||
| Q4 24 | 32.9% | 9.7% | ||
| Q3 24 | 44.3% | 20.1% | ||
| Q2 24 | 16.9% | 8.5% | ||
| Q1 24 | 21.5% | 15.5% |
| Q4 25 | 3.0% | 5.3% | ||
| Q3 25 | 2.6% | 2.3% | ||
| Q2 25 | 2.9% | 1.5% | ||
| Q1 25 | 2.3% | 1.3% | ||
| Q4 24 | 3.1% | 4.0% | ||
| Q3 24 | 2.7% | 2.1% | ||
| Q2 24 | 2.1% | 1.6% | ||
| Q1 24 | 2.4% | 1.4% |
| Q4 25 | 1.82× | — | ||
| Q3 25 | 2.87× | — | ||
| Q2 25 | 2.99× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 61.65× | — | ||
| Q3 24 | 4.62× | — | ||
| Q2 24 | 1.38× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
Revenue Breakdown by Segment
BMY
| Net Product Sales | $12.1B | 97% |
| Zeposia | $159.0M | 1% |
| Opdivo Ovantig | $132.0M | 1% |
| Abecma | $100.0M | 1% |
| Sotyktu | $86.0M | 1% |
VTRS
| Brands | $1.2B | 32% |
| Generics | $1.1B | 29% |
| Lipitor | $377.3M | 10% |
| Norvasc | $175.2M | 5% |
| Other | $136.6M | 4% |
| Lyrica | $119.8M | 3% |
| Viagra | $104.2M | 3% |
| Creon | $98.9M | 3% |
| Epi Pen Auto Injectors | $79.0M | 2% |
| Yupelri | $70.6M | 2% |
| Effexor | $68.1M | 2% |
| Zoloft | $66.8M | 2% |
| Celebrex | $66.2M | 2% |
| Xalabrands | $42.0M | 1% |
| Dymista | $38.6M | 1% |
